

Title (en)

BISPHOSPHONATE/ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.

Title (de)

BIPHOSPHONAT/ÖSTROGEN-THERAPIE ZUR BEHANDLUNG UND PRÄVENTION VON KNOCHENVERLUST.

Title (fr)

THERAPIE UTILISANT DES BISPHOSPHONATES ET DES STROGENES EN VUE DE TRAITER ET DE PREVENIR LA RESORPTION OSSEUSE.

Publication

EP 0675723 A4 19980805 (EN)

Application

EP 94905419 A 19931217

Priority

- US 9312302 W 19931217
- US 99641892 A 19921223

Abstract (en)

[origin: WO9414455A1] Disclosed is a combination therapy for treating and for preventing bone loss by the use of estrogen and a bisphosphonate selected from: alendronate, clodronate, tiludronate, YM175, BM210995, or mixture thereof. Also described is a pharmaceutical composition of the above for carrying out the therapeutic method.

IPC 1-7

A61K 31/66; **A61K 31/56**

IPC 8 full level

A61K 31/565 (2006.01); **A61K 31/66** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)

A61K 31/66 (2013.01); **A61P 43/00** (2017.12)

Citation (search report)

- [X] WO 9214474 A1 19920903 - NORWICH EATON PHARMA [US]
- [X] EP 0496520 A1 19920729 - MERCK & CO INC [US]
- [X] WO 9205187 A1 19920402 - BOEHRINGER MANNHEIM GMBH [DE]
- [X] CIMINERA N. ET AL: "Studio Comparativo degli effetti di estrogeni e difosfonati sulla perdita ossea postmenopausale", ANN. OSTET. GINECOL. MED. PERINAT., vol. 113, no. 5, 1992, pages 232 - 237, XP002064831
- See references of WO 9414455A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

WO 9414455 A1 19940707; AU 5953894 A 19940719; CA 2151240 A1 19940707; EP 0675723 A1 19951011; EP 0675723 A4 19980805; JP H08505142 A 19960604

DOCDB simple family (application)

US 9312302 W 19931217; AU 5953894 A 19931217; CA 2151240 A 19931217; EP 94905419 A 19931217; JP 51531294 A 19931217